Genetically informed lung cancer medicine

被引：50

作者：

Pao, William ^{[1
]}

Iafrate, A. John ^{[2
]}

Su, Zengliu ^{[1
]}

机构：

[1] Vanderbilt Univ, Sch Med, Vanderbilt Ingram Canc Ctr, Dept Med,Div Hematol Oncol, Nashville, TN 37232 USA

[2] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA

来源：

JOURNAL OF PATHOLOGY | 2011年 / 223卷 / 02期

关键词：

lung cancer; signal transduction pathway; gene mutation; protein kinase; targeted therapy; genetic analysis; sequencing; gene fusion; gene rearrangement; SMALL-CELL LUNG; RECEPTOR TYROSINE KINASE; EML4-ALK FUSION GENE; C-MET; PHASE-II; ACQUIRED-RESISTANCE; MUTATIONAL ANALYSIS; SOMATIC MUTATIONS; SIGNALING PATHWAY; PIK3CA GENE;

D O I：

10.1002/path.2788

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Knowledge of tumour mutation status has become increasingly important for the prioritization of targeted therapies for cancer. We review here the major known 'driver' mutations with therapeutic relevance in non-small cell lung cancer. We also discuss a variety of methods now being employed in molecular diagnostic laboratories to detect genetic alterations in lung tumours. A genetically-informed approach to lung cancer medicine is rapidly becoming the standard of care worldwide and should lead to improved outcomes for patients. Copyright (C) 2010 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.

引用

页码：230 / 240

页数：11

共 109 条

[31]

Gansler T, 2010, CA-CANCER J CLIN, V60, P1, DOI [10.3322/caac.20073, 10.3322/caac.20049]

[32] Kinases as targets in the treatment of solid tumors [J].

Giamas, Georgios ;

Man, Yik L. ;

Hirner, Heidrun ;

Bischof, Joachim ;

Kramer, Klaus ;

Khan, Kalimullah ;

Ahmed, Sharmeen S. Lavina ;

Stebbing, Justin ;

Knippschild, Uwe .

CELLULAR SIGNALLING, 2010, 22 (07) :984-1002

[33] ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling [J].

GrausPorta, D ;

Beerli, RR ;

Daly, JM ;

Hynes, NE .

EMBO JOURNAL, 1997, 16 (07) :1647-1655

[34] Cell growth control by G protein-coupled receptors: from signal transduction to signal integration [J].

Gutkind, JS .

ONCOGENE, 1998, 17 (11) :1331-1342

[35] Down-regulation of MET, the receptor for hepatocyte growth factor [J].

Hammond, DE ;

Urbé, S ;

Woude, GFV ;

Clague, MJ .

ONCOGENE, 2001, 20 (22) :2761-2770

[36] Optimization of patient selection for gefitinib in non-small cell lung cancer by combined analysis of epidermal growth factor receptor mutation, K-ras mutation, and Akt phosphorylation [J].

Han, SW ;

Kim, TY ;

Jeon, YK ;

Hwang, PG ;

Im, SA ;

Lee, KH ;

Kim, JH ;

Kim, DW ;

Heo, DS ;

Kim, NK ;

Chung, DH ;

Bang, YJ .

CLINICAL CANCER RESEARCH, 2006, 12 (08) :2538-2544

[37] Next-generation genomics: an integrative approach [J].

Hawkins, R. David ;

Hon, Gary C. ;

Ren, Bing .

NATURE REVIEWS GENETICS, 2010, 11 (07) :476-486

[38]

Heinmöller P, 2003, CLIN CANCER RES, V9, P5238

[39] Comparison of genotyping with direct sequencing as a method to detect EGFR mutations in NSCLC [J].

Holmes, A. ;

Joshi, V. A. ;

Kuang, Y. ;

Rogers, A. ;

Jaenne, P. A. .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)

[40] Regulator of G-protein signaling (RGS) proteins in cancer biology [J].

Hurst, Jillian H. ;

Hooks, Shelley B. .

BIOCHEMICAL PHARMACOLOGY, 2009, 78 (10) :1289-1297

← 1 2 3 4 5 6 7 8 9 10 →